Phase 2 N=124 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: Progression-free Survival by CYP2D6 Status in 2 Categories — 12.9; 6.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Estrogen Receptor-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer · Recurrent Breast Cancer
Primary: Clinical Benefit Rate (CR + PR + SD > 6 Months). — 7.1; 6.3 Percent of Participants
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=21 Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Number of Participants With Partial and Complete Response. — 1 participant
Phase 2 N=65 Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
Breast Cancer
Primary: Number of Participants With Grade 3+ Treatment-related Skin, Fibrosis, and Breast Pain Adverse Events — 1 participants
Phase 3 N=162 Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 57; 69 percentage of participants
N/A N=13 Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence Rates — 0; 0 percentage of participants
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Phase 2 N=30 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Triple Negative Breast Cancer · Endometrial Cancer · Hormone Receptor Positive, HER2 Negative Breast Cancer
Primary: Cohort 1 - Progression-free Survival (PFS) — 1.9 Months
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Phase 3 N=852 The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Locally Recurrent Breast Cancer · Metastatic Breast Cancer
Primary: Kaplan-Meier Estimate of Overall Survival: Intention to Treat (ITT) Population — 12.4; 10.3 Months — p== 0.0835
Phase 2 N=48 Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=32 Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 16 Months
Phase 3 N=564 S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo
Breast Cancer
Primary: Overall Survival — 10.7; 12.5 months — p=0.98
Phase 2 N=43 BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=19 Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With Tumor Response — 5; 9; 1; 3 participants
N/A N=66 Intraoperative Radiotherapy After Local Recurrence in Breast Cancer
Breast Carcinoma
Primary: The Tolerance of RIOP (Intra Operative Radiotherapy) in Patients With Delayed Local Recurrences, After a Second Conservative Treatment of Breast Cancer — 34; 19…
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=31 Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
Breast Cancer
Primary: Median Time to Progression — 149 Days
Phase 3 N=475 A Phase III Trial For Patients With Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms · Cancer of the Breast
Primary: Time to Disease Progression (Initial Treatment) — 9.28; 8.88 months — p=0.385
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
N/A N=1,267 An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Breast Cancer
Primary: Progression Free Survival — 8.54; 12.88 months
N/A N=129 Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy
Disseminated HER2+ Breast Cancer
Primary: The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) — 63.5; 48.8; 84.1; 41.1 percentage of participants
Phase 2 N=22 Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Progesterone Receptor Negative
Primary: PFS Status — 1.2 months
Phase 3 N=724 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Breast Cancer
Primary: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. — 6.93; 2.83 months — p=<0.0001
Phase 2 N=37 Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms, Male · Carcinoma, Ductal
Primary: Overall Tumor Response — 1; 8; 14; 9 participants